Article Text

Download PDFPDF
Rituximab in Churg-Strauss syndrome
  1. M Koukoulaki1,
  2. K G C Smith1,2,
  3. D R W Jayne1
  1. 1Vasculitis and SLE Unit, Department of Medicine, University of Cambridge School of Clinical Medicine, UK
  2. 2Cambridge Institute for Medical Research, University of Cambridge School of Clinical Medicine, UK
  1. Correspondence to:
    Dr D R W Jayne
    Vasculitis and SLE Unit, Department of Medicine, Addenbrooke’s Hospital, Cambridge CB2 2QQ, UK; dj106{at}

Statistics from

Churg-Strauss Syndrome (CSS) is a small vessel systemic vasculitis, characterised by asthma, peripheral eosinophilia, neuropathy, pulmonary infiltrates, and sinus abnormalities.1 Conventional treatment with corticosteroids and cyclophosphamide2 controls disease activity; however, relapse is frequent and the treatment is toxic. Alternative treatments include plasma exchange,3 interferon alfa,4 and intravenous immunoglobulin.5 B cell depletion with rituximab has proved effective in autoimmune diseases, including rheumatoid arthritis, systemic lupus erythematosus, and antineutrophil cytoplasmic antibody (ANCA) associated vasculitis.6 We present two cases of patients with refractory CSS who were successfully treated with rituximab.

A 37 year old woman (case 1) presented with an 8 month history of nasal congestion, hearing loss, lymphadenopathy, rash, breast inflammation, peripheral neuropathy, abdominal pain, malaise, and weight loss. Tachydysrhythmias with poor left ventricular function on echocardiogram suggested cardiac vasculitis. Bone …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.